Uveal melanoma prognostication: From lesion size and cell type to molecular class

Canadian Journal of Ophthalmology

Volumn 47, Issue 3, 2012, Pages 246-253

  Gill, Harmeet S ^a,c,d   Char, Devron H ^a,b,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Tumori Foundation   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; SELUMETINIB; SORAFENIB; TICILIMUMAB;

ADVANCED CANCER; ARTICLE; ASPIRATION BIOPSY; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SIZE; CANCER SURVIVAL; CLINICAL PRACTICE; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; DATA ANALYSIS; EMBASE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC SCREENING; HISTOPATHOLOGY; HUMAN; INFORMATION RETRIEVAL; MEDLINE; METASTASIS; MICROARRAY ANALYSIS; MOLECULAR BIOLOGY; MOLECULAR GENETICS; MONOSOMY; MORTALITY; PHASE 2 CLINICAL TRIAL (TOPIC); PROGNOSIS; UVEA MELANOMA;

EID: 84862272416     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/j.jcjo.2012.03.038     Document Type: Review

References (94)

1. Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology. 2003;110:956-61. (Pubitemid 36560496)
2. Collaborative Ocular Melanoma Study Group. TheCOMSrandomized trial of iodine 125 brachytherapy for choroidal melanoma, V: Twelveyear mortality rates and prognostic factors, COMS Report No. 28. Arch Ophthalmol. 2006;124:1684-93.
3. Augsburger JJ, Corrêa ZM, Shaikh AH. Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol. 2009;148:119-27.
4. Diener-West M, Reynolds SM, Agugliaro DJ, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study, Group Report No. 26. Arch Ophthalmol. 2005;123:1639-43. (Pubitemid 41785095)
5. Prescher G, Bornfeld N, Hirche H, et al. Prognostic implications of monosomy 3 in uveal melanoma. Lancet. 1996;347:1222-5. (Pubitemid 26131850)
6. Onken MD, Worley LA, Ehlers JP, et al. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004;64:7205-9. (Pubitemid 39372052)
7. Harbour JW, Onken MD, Roberson EDO, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330:1410-3.
8. Zimmerman LE, McLean IW, Foster WD. Does enucleation of the eye containing a malignant melanoma prevent or accelerate dissemination of tumour cells. Br J Ophthalmol. 1978;62:420-5. (Pubitemid 8357372)
9. Manschot WA, Strik Ry. Is irradiation a justifiable treatment of choroidal melanoma? Analysis of published results. Br J Ophthalmol. 1987;71: 348-52. (Pubitemid 17072276)
10. The Collaborative Ocular Melanoma Study Group. Accuracy of diagnosis of choroidal melanomas in the Collaborative Ocular Melanoma Study, COMS Report No. 1. Arch Ophthalmol. 1990;108:1268-73.
11. Finger PT. Radiation therapy for choroidal melanoma. Surv Ophthalmol. 1997;42:215-32. (Pubitemid 27509826)
12. Singh AD, Topham A. Survival rates with uveal melanoma in the United States: 1973-1997. Ophthalmology. 2003;110:962-5. (Pubitemid 36560497)
13. Gragoudas E, Li W, Goitein M, et al. Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. Arch Ophthalmol. 2002;120:1665-71. (Pubitemid 36401801)
14. Jampol LM, Moy CS, Murray TG, et al. TheCOMSrandomized trial of iodine 125 brachytherapy for choroidal melanoma, IV: Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS Report No. 19. Ophthalmology. 2002;109:2197-206. (Pubitemid 35417099)
15. Callender GR. Malignant melanotic tumours of the eye: A study of histologic types in 111 cases. Trans Am Acad Ophthalmol Otolaryngol. 1931;36:131-42.
16. McLean IW, Foster WD, Zimmerman LE, Gamel JW. Modifications of Callender's classification of uveal melanoma at the Armed Forces Institute of Pathology. Am J Ophthalmol. 1983;96:502-9. (Pubitemid 13012002)
17. Grossniklaus HE, Oakman JH, Cohen C, et al. Histopathology, morphometry, and nuclear DNA content of iris melanocytic lesions. Invest Ophthalmol Vis Sci. 1995;36:745-50.
18. Pe'er J, Rummelt V, Mawn L, et al. Mean of the ten largest nucleoli, microcirculation architecture, and prognosis of ciliochoroidal melanomas. Ophthalmology. 1994;101:1227-35. (Pubitemid 24236081)
19. Folberg R, Rummelt V, Parys-Van Ginderdeuren R, et al. The prognostic value of tumour blood vessel morphology in primary uveal melanoma. Ophthalmology. 1993;100:1389-98. (Pubitemid 23274035)
20. Marcus DM, Minkovitz JB, Wardwell SD, Albert DM, the Collaborative Ocular Melanoma Study Group. The value of nucleolar organizer regions in uveal melanoma. Am J Ophthalmol. 1990;110:527-34. (Pubitemid 20360683)
21. McLean IW, Keefe KS, Burnier MN. Uveal melanoma. Comparison of the prognostic value of fibrovascular loops, mean of the ten largest nucleoli, cell type, and tumour size. Ophthalmology. 1997;104:777-80. (Pubitemid 27200874)
22. Eskelin S, Pyrhönen S, Summanen P, et al. Tumour doubling times in metastatic malignant melanoma of the uvea: Tumour progression before and after treatment. Ophthalmology. 2000;107:1443-9.
23. Callejo SA, Antecka E, Blanco PL, et al. Identification of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma: A prospective longitudinal study. Eye. 2007;21: 752-9. (Pubitemid 46909176)
24. Seregard S, Spångberg B, Juul C, Oskarsson M. Prognostic accuracy of the mean of the largest nucleoli, vascular patterns, and PC-10 in posterior uveal melanoma. Ophthalmology. 1998;105:485-91. (Pubitemid 28125103)
25. Barak V, Frenkel S, Kalickman I, et al. Serum markers to detect metastatic uveal melanoma. Anticancer Res. 2007;27:1897-900. (Pubitemid 46954694)
26. Missotten GS, Korse CM, van Dehn C, et al. S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening: A comparison with liver function tests. Tumour Biol. 2007;28:63-9. (Pubitemid 46328593)
27. Krishnakumar S, Abhyankar D, Lakshmi SA, et al. HLA expression in choroidal melanomas: Correlation with clinicopathological features. Curr Eye Res. 2004;28:409-16. (Pubitemid 39090324)
28. Maat W, van der Slik AR, Verhoeven DH, et al. Evidence for natural killer cell-mediated protection from metastasis formation in uveal melanoma patients. Invest Ophthalmol Vis Sci. 2009;50:2888-95.
29. Kishore K, Ghazvini S, Char DH, et al. p53 gene and cell cycling in uveal melanoma. Am J Ophthalmol. 1996;121:561-7. (Pubitemid 26135865)
30. Erol N, Oner U, Artan S, et al. Chromosomal abnormalities, p53 and Bcl-2 expression and clinical outcome in choroidal melanoma. Melanoma Res. 2004;14:473-8. (Pubitemid 40221137)
31. White VA, Chambers JD, Courtright PD, et al. Correlation of cytogenetic abnormalities with the outcome of patients with uveal melanoma. Cancer. 1998;83:354-9. (Pubitemid 28317816)
32. Horsman DE, White VA. Cytogenetic analysis of uveal melanoma: Consistent occurrence of monosomy 3 and trisomy 8q. Cancer. 1993; 71:811-9. (Pubitemid 23051386)
33. Sisley K, Rennie IG, Cottam DW, et al. Cytogenetic findings in six posterior uveal melanomas: involvement of chromosomes 3, 6, and 8. Genes Chromosomes Cancer. 1990;2:205-9. (Pubitemid 20369595)
34. Scholes AGM, Damato BE, Nunn J, et al. Monosomy 3 in uveal melanoma: Correlation with clinical and histologic predictors of survival. Invest Ophthalmol Vis Sci. 2003;44:1008-11. (Pubitemid 36297813)
35. Patel KA, Edmondson ND, Talbot F, et al. Prediction of prognosis in patients with uveal melanoma using fluorescence in situ hybridization. Br J Ophthalmol. 2001;85:1440-4. (Pubitemid 34032910)
36. Aalto Y, Eriksson L, Seregard S, et al. Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma. Invest Ophthalmol Vis Sci. 2001;42: 313-7. (Pubitemid 32121456)
37. Prescher G, Bornfeld N, Horsthemke B, Becher R. Chromosomal aberrations defining uveal melanoma of poor prognosis. Lancet. 1992;339: 691-2.
38. Parrella P, Sidransky D, Merbs SL. Allelotype of posterior uveal melanoma: implications for a bifurcated tumour progression pathway. Cancer Res. 1999;59:3032-7. (Pubitemid 29315995)
39. Onken MD, Worley LA, Person E, et al. Loss of heterozygosity of chromosome 3 detected with single nucleotide polymorphisms is superior to monosomy 3 for predicting metastasis in uveal melanoma. Clin Cancer Res. 2007;13:2923-7. (Pubitemid 46849567)
40. Worley LA, Onken MD, Person E, et al. Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma. Clin Cancer Res. 2007;13:1466-71. (Pubitemid 46450436)
41. Tschentscher F, Hüsing J, Hölter T, et al. Tumour classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct clinical entities. Cancer Res. 2003;63:2578-84. (Pubitemid 36608917)
42. Onken MD, Ehlers JP, Worley LA, et al. Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanoma. Cancer Res. 2006;66:4602-9.
43. Ehlers JP, Worley L, Onken MD, et al. Integrative genomic analysis of aneuploidy in uveal melanoma. Clin Cancer Res. 2008;14:115-22. (Pubitemid 351377985)
44. Onken MD, Worley LA, Harbour JW. A metastasis modifier locus on human chromosome 8p in uveal melanoma identified by integrative genomic analysis. Clin Cancer Res. 2008;14:3737-45.
45. Harbour JW. Eye cancer: unique insights into oncogenesis: The Cogan Lecture. Invest Ophthalmol Vis Sci. 2006;47:1736-45.
46. Singh AD, Wang MX, Donoso LA, et al. Genetic aspects of uveal melanoma: a brief review. Semin Oncol. 1996;23:768-72. (Pubitemid 26424706)
47. McCannel TA, Burgess BL, Rao NP, et al. Identification of candidate tumour oncogenes by integrative molecular analysis of choroidal melanoma fine-needle aspiration biopsy specimens. Arch Ophthalmol. 2010; 128:1170-7.
48. Massaro-Giordano M, Baldi G, De Luca A, et al. Differential expression of the retinoblastoma gene family members in choroidal melanoma: Prognostic significance. Clin Cancer Res. 1999;5:1455-8. (Pubitemid 29282952)
49. Buecher B, Gauthier-Villars M, Desjardins L, et al. Contribution of CDKN2A/P16 (INK4A);P14 (ARF), CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predisposition to uveal melanoma. Fam Cancer. 2010;9:663-7.
50. Smith JH, Padnick-Silver L, Newlin A, et al. Genetic study of familial uveal melanoma: Association of uveal and cutaneous melanoma with cutaneous and ocular nevi. Ophthalmology. 2007;114:774-9. (Pubitemid 46505166)
51. Singh AD, Wang MX, Donoso LA, et al. Familial uveal melanoma, III. Is the occurrence of familial uveal melanoma coincidental? Arch Ophthalmol. 1996;114:1101-4.
52. Abdel-Rahman MH, Pilarski R, Cebulla CM, et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet. 2011;48:856-9.
53. Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43:1022-5.
54. Goldstein AM. Germline BAP1 mutations and tumour susceptibility. Nat Genet. 2011;43:925-6.
55. Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009; 457:599-602.
56. Onken MD, Worley LA, Long MD, et al. Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci. 2008; 49:5230-4.
57. Bauer J, Kilic E, Vaarwater J, et al. Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma. Br J Cancer. 2009;101:813-5.
58. Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010;363:2191-9.
59. Weber A, Hengge UR, Urbanik D, et al. Absense of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea. Lab Invest. 2003;83:1771-6. (Pubitemid 38018540)
60. Onken MD, Worley LA, Tuscan MD, Harbour JW. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn. 2010;12:461-8.
61. Kilic E, van Gils W, Lodder E, et al. Clinical and cytogenetic analyses in uveal melanoma. Invest Ophthalmol Vis Sci. 2006;47:3703-7. (Pubitemid 46044279)
62. Damato B, Duke C, Coupland SE, et al. Cytogenetics of uveal melanoma: a 7-year clinical experience. Ophthalmology. 2007;114:1925-31.
63. Shields CL, Ganguly A, Bianciotto CG, et al. Prognosis of uveal melanoma in 500 cases using genetic testing of fine-needle aspiration biopsy specimens. Ophthalmology. 2011;118:396-401.
64. Chappell MC, Char DH, Cole TB, et al. Uveal melanoma: molecular pattern, clinical features, and radiation response. In press.
65. Coupland SE, Campbell I, Damato B. Routes of extraocular extension of uveal melanoma: Risk factors and influence on survival probability. Ophthalmology. 2008;115:1778-85.
66. Damato B, Coupland SE. Translating uveal melanoma cytogenetics into clinical care. Arch Ophthalmol. 2009;127:423-9.
67. Shields CL, Materin MA, Teixeira L, et al. Small choroidal melanoma with chromosome 3 monosomy on fine-needle aspiration biopsy. Ophthalmology. 2007;114:1919-24. (Pubitemid 47483932)
68. Onken MD, Worley LA, Harbour JW. Association between gene expression profile, proliferation and metastasis in uveal melanoma. Curr Eye Res. 2010;35:857-63.
69. Coupland SE, Vorum H, Mandal N, et al. Proteomics of uveal melanomas suggests HSP-27 as a possible surrogate marker of chromosome 3 loss. Invest Ophthalmol Vis Sci. 2010;51:12-20.
70. Trolet J, Hupé P, Huon I, et al. Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumours and liver metastases. Invest Ophthalmol Vis Sci. 2009;50:2572-80.
71. Meir T, Dror R, Yu X, et al. Molecular characteristics of liver metastases from uveal melanoma. Invest Ophthalmol Vis Sci. 2007;48:4890-6. (Pubitemid 351260893)
72. Damato B, Dopierala JA, Coupland SE. Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification. Clin Cancer Res. 2010;16:6083-92.
73. Lake SL, Coupland SE, Taktak AF, Damato BE. Whole-genome microarray detects deletions and loss of heterozygosity of chromosome 3 occurring exclusively in metastasizing uveal melanoma. Invest Ophthalmol Vis Sci. 2010;51:4884-91.
74. Mensink HW, Vaarwater J, Kiliç E, et al. Chromosome 3 intratumour heterogeneity in uveal melanoma. Invest Ophthalmol Vis Sci. 2009;50: 500-4.
75. Dopierala J, Damato BE, Lake SL, et al. Genetic heterogeneity in uveal melanoma assessed by multiplex ligation-dependent probe amplification. Invest Ophthalmol Vis Sci. 2010;51:4898-905.
76. Shields CL, Ganguly A, Materin MA, et al. Chromosome 3 analysis of uveal melanoma using fine-needle aspiration biopsy at the time of plaque radiotherapy in 140 consecutive cases: The Deborah Iverson, MD, Lectureship. Arch Ophthalmol. 2007;125:1017-24. (Pubitemid 47258031)
77. Tao LC, Pearson FG, Delarue NC, et al. Percutaneous fine-needle aspiration biopsy. I. Its value to clinical practice. Cancer. 1980;45:1480-5. (Pubitemid 10134887)
78. Char DH, Kroll SM, Miller T, et al. Irradiated uveal melanomas: cytopathologic correlation with prognosis. Am J Ophthalmol. 1996;122: 509-13. (Pubitemid 26329685)
79. Shields JA, Shields CL, Ehya H, et al. Fine-needle aspiration biopsy of suspected intraocular tumours: The 1992 Urwick Lecture. Ophthalmology. 1993;100:1677-84. (Pubitemid 23335932)
80. Augsburger JJ, Shields JA, Folberg R, et al. Fine-needle aspiration biopsy in the diagnosis of intraocular cancer: Cytologic-histologic correlations. Ophthalmology. 1985;92:39-49. (Pubitemid 15170412)
81. Jakobiec FA, Coleman DJ, Chattock A, Smith M. Ultrasonographically guided needle biopsy and cytologic diagnosis of solid intraocular tumours. Ophthalmology. 1979;86:1662-81.
82. Midena E, Bonaldi L, Parrozzani R, et al. In vivo detection of monosomy 3 in eyes with medium-sized uveal melanoma using transscleral fine needle aspiration biopsy. Eur J Ophthalmol. 2006;16:422-5. (Pubitemid 44049285)
83. Sen J, Groenewald C, Hiscott PS, et al. Transretinal choroidal tumour biopsy with a 25-gauge vitrector. Ophthalmology. 2006;113:1028-31. (Pubitemid 43795203)
84. Müller-Horvat C, Radny P, Eigentler TK, et al. Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma. Eur J Cancer. 2006;42:342-50. (Pubitemid 43132889)
85. Eskelin S, Pyrhönen S, Summanen P, et al. A prognostic model and staging for metastatic uveal melanoma. Cancer. 1999;85:1151-9.
86. Hendler K, Pe'er J, Kaiserman I, et al. Trends in liver function tests: A comparison with serum tumour markers in metastatic uveal melanoma (part 2). Anticancer Res. 2011;31:351-7.
87. Kaiserman I, Amer R, Pe'er J. Liver function tests in metastatic uveal melanoma. Am J Ophthalmol. 2004;137:236-43. (Pubitemid 38220994)
88. Gombos DS, Van Quill KR, Uusitalo M, O'Brien JM. Geographic disparities in diagnostic screening for metastatic uveal melanoma. Ophthalmology. 2004;111:2254-8. (Pubitemid 39575596)
89. Gragoudas ES, Egan KM, Seddon JM, et al. Survival of patients with metastases from uveal melanoma. Ophthalmology. 1991;98:383-9; discussion: 90.
90. Kim IK, Lane AM, Gragoudas ES. Survival in patients with presymptomatic diagnosis of metastatic uveal melanoma. Arch Ophthalmol. 2010;128:871-5.
91. Augsburger JJ, Corrêa ZM, Trichopoulos N. Surveillance testing for metastasis from primary uveal melanoma and effect on patient survival. Am J Ophthalmol. 2011;152:5-9.
92. Landreville S, Agapova OA, Harbour JW. Emerging insights into the molecular pathogenesis of uveal melanoma. Future Oncol. 2008;4: 629-36.
93. Patel M, Smyth E, Chapman PB, et al. Therapeutic implications of the emerging molecular biology of uveal melanoma. Clin Cancer Res. 2011; 17:2087-100.
94. Villanueva J, Vultur A, Herlyn M. Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options. Cancer Res. 2011;71: 7137-40.